Phase II Study of Bendamustine and Ofatumumab in Elderly Patients with Newly Diagnosed Diffuse Large B‐Cell Lymphoma Who Are Poor Candidates for R‐CHOP Chemotherapy

por Flinn, Ian W., Erter, Jack, Daniel, Davey B., Mace, Joseph R., Berdeja, Jesus G.
Publicado 2019

Safety, tolerability, and preliminary activity of IMGN529, a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a dose-esca...

por Stathis, Anastasios, Flinn, Ian W., Madan, Sumit, Maddocks, Kami, Freedman, Arnold, Weitman, Steven, Zucca, Emanuele, Munteanu, Mihaela C., Lia Palomba, M.
Publicado 2018

A Phase II Trial Evaluating the Safety of Rapid Infusion of Ofatumumab in Patients with Previously Treated Chronic Lymphocytic Leukemia

por Donnellan, William, Berdeja, Jesus G., Shipley, Diana, Arrowsmith, Edward R., Wright, David, Lunin, Scott, Brown, Richard, Essell, James H., Flinn, Ian W.
Publicado 2017

A phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed or relapsed/refractory multiple myeloma: Final analysis of second dose‐expansion coh...

por Berdeja, Jesus G., Gregory, Tara K., Faber, Edward A., Hart, Lowell L., Mace, Joseph R., Arrowsmith, Edward R., Flinn, Ian W., Matous, Jeffrey V.
Publicado 2021

Duvelisib, an oral dual PI3K‐δ, γ inhibitor, shows clinical activity in indolent non‐Hodgkin lymphoma in a phase 1 study

por Flinn, Ian W., Patel, Manish, Oki, Yasuhiro, Horwitz, Steven, Foss, Francine F., Allen, Kerstin, Douglas, Mark, Stern, Howard, Sweeney, Jennifer, Kharidia, Jahnavi, Kelly, Patrick, Kelly, Virginia M., Kahl, Brad
Publicado 2018

A Phase I Study of Pelabresib (CPI-0610), a Small-Molecule Inhibitor of BET Proteins, in Patients with Relapsed or Refractory Lymphoma

por Blum, Kristie A., Supko, Jeffrey G., Maris, Michael B., Flinn, Ian W., Goy, Andre, Younes, Anas, Bobba, Suresh, Senderowicz, Adrian M., Efuni, Sergey, Rippley, Ronda, Colak, Gozde, Trojer, Patrick, Abramson, Jeremy S.
Publicado 2022

P628: UPDATED ANALYSIS OF BELLWAVE-001: A PHASE 1/2 OPEN-LABEL DOSE-EXPANSION STUDY OF THE EFFICACY AND SAFETY OF NEMTABRUTINIB FOR THE TREATMENT OF B-CELL MALIGNANCIES

por Woyach, Jennifer, Flinn, Ian W., Awan, Farrukh, Eradat, Herbert, Brander, Danielle M., Tees, Michael, Parikh, Sameer, Phillips, Tycel, Ghori, Razi, Paydar, Ima, Farooqui, Mohammed Z. H., Byrd, John C., Stephens, Deborah
Publicado 2023

PB1926: EFFICACY AND SAFETY OF ONCE DAILY (QD) VS TWICE DAILY (BID) ZANUBRUTINIB FOR PATIENTS WITH VARIOUS B-CELL MALIGNANCIES: A COMPARATIVE SUMMARY OF CLINICAL DATA AND EXPOSURE-...

por Tam, Constantine, Shadman, Mazyar, Sharman, Jeff, Cull, Gavin, Phillips, Tycel, Trotman, Judith, Cohen, Aileen, Allewelt, Heather, Crescenzo, Rocco, Delarue, Richard, Zhang, Heather, Tariq, Bilal, Sahasranaman, Sri, Ou, Ying C, Flinn, Ian W
Publicado 2023

Prospective SPECT-CT Organ Dosimetry-Driven Radiation-Absorbed Dose Escalation Using the In-111 ((111)In)/Yttrium 90 ((90)Y) Ibritumomab Tiuxetan (Zevalin(®)) Theranostic Pair in P...

por Wahl, Richard L., Frey, Eric C., Jacene, Heather A., Kahl, Brad S., Piantadosi, Steven, Bianco, Jesus A., Hammes, Richard J., Jung, Miah, Kasecamp, Wayne, He, Bin, Sgouros, George, Flinn, Ian W., Swinnen, Lode J.
Publicado 2021

Analysis of the potential effect of ponatinib on the QTc interval in patients with refractory hematological malignancies

por Sonnichsen, Daryl, Dorer, David J., Cortes, Jorge, Talpaz, Moshe, Deininger, Michael W., Shah, Neil P., Kantarjian, Hagop M., Bixby, Dale, Mauro, Michael J., Flinn, Ian W., Litwin, Jeffrey, Turner, Christopher D., Haluska, Frank G.
Publicado 2013

First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL

por Byrd, John C., Smith, Stephen, Wagner-Johnston, Nina, Sharman, Jeff, Chen, Andy I., Advani, Ranjana, Augustson, Bradley, Marlton, Paula, Renee Commerford, S., Okrah, Kwame, Liu, Lichuan, Murray, Elaine, Penuel, Elicia, Ward, Ashley F., Flinn, Ian W.
Publicado 2018

Correction: First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL

por Byrd, John C., Smith, Stephen, Wagner-Johnston, Nina, Sharman, Jeff, Chen, Andy I., Advani, Ranjana, Augustson, Bradley, Marlton, Paula, Commerford, S. Renee, Okrah, Kwame, Liu, Lichuan, Murray, Elaine, Penuel, Elicia, Ward, Ashley F., Flinn, Ian W.
Publicado 2019

Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE stu...

por Greil, Richard, Tedeschi, Alessandra, Moreno, Carol, Anz, Bertrand, Larratt, Loree, Simkovic, Martin, Gill, Devinder, Gribben, John G., Flinn, Ian W., Wang, Zhengyuan, Cheung, Leo W. K., Nguyen, Aaron N., Zhou, Cathy, Styles, Lori, Demirkan, Fatih
Publicado 2021

First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE...

por Moreno, Carol, Greil, Richard, Demirkan, Fatih, Tedeschi, Alessandra, Anz, Bertrand, Larratt, Loree, Simkovic, Martin, Novak, Jan, Strugov, Vladimir, Gill, Devinder, Gribben, John G., Kwei, Kevin, Dai, Sandra, Hsu, Emily, Dean, James P., Flinn, Ian W.
Publicado 2022

Idelalisib in Combination With Rituximab or Bendamustine or Both in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia

por Coutre, Steven E., Flinn, Ian W., de Vos, Sven, Barrientos, Jacqueline C., Schreeder, Marshall T., Wagner-Johnson, Nina D., Sharman, Jeff P., Boyd, Thomas E., Fowler, Nathan, Dreiling, Lyndah, Kim, Yeonhee, Mitra, Siddhartha, Rai, Kanti, Leonard, John P., Furman, Richard R.
Publicado 2018

Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic Leukemia

por Allan, John N., Flinn, Ian W., Siddiqi, Tanya, Ghia, Paolo, Tam, Constantine S., Kipps, Thomas J., Barr, Paul M., Elinder Camburn, Anna, Tedeschi, Alessandra, Badoux, Xavier C., Jacobs, Ryan, Kuss, Bryone J., Trentin, Livio, Zhou, Cathy, Szoke, Anita, Abbazio, Christopher, Wierda, William G.
Publicado 2023

PB2346: ZUMA-24: A PHASE 2, OPEN-LABEL, MULTICENTER STUDY OF AXICABTAGENE CILOLEUCEL IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA GIVEN WITH CORTICOSTEROIDS IN THE OU...

por Leslie, Lori, Tees, Michael, Flinn, Ian W., Rodriguez, Tulio, Baird, John H., Deol, Abhinav, Mead, Monica, Bachier, Carlos, Rapoport, Aaron P., Mcclune, Brian, Hoda, Daanish, Perales, Miguel-Angel, Zheng, Yan, Filosto, Simone, Davis1, Madison, Miao, Harry, Kim, Jenny J., Oluwole, Olalekan O.
Publicado 2023

P1107: ZUMA-22: A PHASE 3, RANDOMIZED CONTROLLED STUDY OF AXICABTAGENE CILOLEUCEL VERSUS STANDARD-OF-CARE THERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA

por Flinn, Ian W., Jacobson, Caron, Nastoupil, Loretta J., Morschhauser, Franck, Davies, Andrew J., Buske, Christian, Corradini, Paolo, Lopez-Guillermo, Armando, Reshef, Ran, Parameswaran, Vinod, Sehgal, Alison, Tees, Michael, Lui, Christine, Xue, Wei, Beygi, Sara, Grechko, Nikolay, Bolsue, Pisita, Giovanetti, Alessandro, To, Christina, Nahas, Myrna
Publicado 2023

Real‐world clinical experience in the Connect(®) chronic lymphocytic leukaemia registry: a prospective cohort study of 1494 patients across 199 US centres

por Mato, Anthony, Nabhan, Chadi, Kay, Neil E., Weiss, Mark A., Lamanna, Nicole, Kipps, Thomas J., Grinblatt, David L., Flinn, Ian W., Kozloff, Mark F., Flowers, Christopher R., Farber, Charles M., Kiselev, Pavel, Swern, Arlene S., Sullivan, Kristen, Flick, E. Dawn, Sharman, Jeff P.
Publicado 2016

The long noncoding RNA, treRNA, decreases DNA damage and is associated with poor response to chemotherapy in chronic lymphocytic leukemia

por Miller, Cecelia R., Ruppert, Amy S., Fobare, Sydney, Chen, Timothy L., Liu, Chaomei, Lehman, Amy, Blachly, James S., Zhang, Xiaoli, Lucas, David M., Grever, Michael R., Tallman, Martin S., Flinn, Ian W., Rassenti, Laura Z., Kipps, Thomas J., Sampath, Deepa, Coombes, Kevin R., Hertlein, Erin K.
Publicado 2017